Protective Effects of Resveratrol Against Adenomyosis in a Mouse Model
article
OA: gold
CC0
⤵ 2 in-corpus citations
AI-generated summary
Resveratrol treatment slowed adenomyosis progression in mice by improving pain sensitivity, reducing fibrosis, and restoring gene expression, despite causing weight loss.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Adenomyosis is a uterine condition in which endometrial glands and stroma are commonly pathologically observed in the myometrium. In this study, we sought to determine the effect of resveratrol on the progression of adenomyosis. Adenomyosis was induced in mice given tamoxifen neonatally. All mice were subjected to body weight measurement and hotplate testing every four weeks beginning four weeks after birth. All mice with adenomyosis were randomly separated into 3 groups at 16 weeks: untreated, low-dose resveratrol (25 mg/kg), and high-dose resveratrol (50 mg/kg). After 3 weeks of treatment, final hotplate test and body weight measurement were performed, and the uterine horn blood samples were collected. Adenomyosis in mice caused body weight loss and uterine weight gain, reduced hotplate latency, and progression of endometrial fibrosis. The underlying biological process could be coupled with the overexpression of many cells' proliferation and immune-regulation-related genes. Resveratrol treatment could slow the progression of adenomyosis by enhancing hotplate latency, lowering endometrial fibrosis, and restoring cell proliferation- and immune-regulation-associated gene expression levels in endometrium and plasma. However, resveratrol treatment also reduced the body weight and uterine weight. In conclusion, Resveratrol might be a potential compound for treating patients with adenomyosis.
My notes (saved in your browser only)
Condition tags
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (37)
- Adenomyosis: A Clinical Review of a Challenging Gynecologic Condition via openalex
- Adenomyosis and Infertility—Review of Medical and Surgical Approaches via openalex
- Adenomyosis: a systematic review of medical treatment via openalex
- Anti-platelet therapy holds promises in treating adenomyosis: experimental evidence via openalex
- Diagnosing adenomyosis: an integrated clinical and imaging approach via openalex
- Diagnosis of adenomyosis: a review. via openalex
- Dysmenorrhea and its severity are associated with increased uterine contractility and overexpression of oxytocin receptor (OTR) in women with symptomatic adenomyosis via openalex
- Plasma High Mobility Group Box 1 (HMGB1), Osteopontin (OPN), and Hyaluronic Acid (HA) as Admissible Biomarkers for Endometriosis via openalex
- Possible Loss of GABAergic Inhibition in Mice With Induced Adenomyosis and Treatment With Epigallocatechin-3-Gallate Attenuates the Loss With Improved Hyperalgesia via openalex
- Resveratrol Reduces Myometrial Infiltration, Uterine Hyperactivity, and Stress Levels and Alleviates Generalized Hyperalgesia in Mice With Induced Adenomyosis via openalex
- Therapeutic options for adenomyosis: a review via openalex
- W2118986158 via openalex
- W2121755881 via openalex
- W2307456086 via openalex
- W2400232021 via openalex
- W2528197635 via openalex
- W2033363713 via openalex
- W2765211929 via openalex
- W2804552465 via openalex
- W2891824977 via openalex
- W2913875557 via openalex
- W2920775222 via openalex
- W2922267617 via openalex
- W2948615087 via openalex
- W2992878053 via openalex
- W1971497655 via openalex
- W3011177534 via openalex
- W1881147845 via openalex
- W3134512791 via openalex
- W3210978776 via openalex
- W4281263418 via openalex
- W2058170926 via openalex
- W4283773794 via openalex
- W2088184271 via openalex
- W2106426362 via openalex
- W2109413567 via openalex
- W2116415854 via openalex
Cited by (2)
Source provenance
- europepmc
- last seen: 2026-06-04T01:30:01.192114+00:00
- openalex
- last seen: 2026-06-04T00:00:01.174412+00:00
- pubmed
- last seen: 2026-05-25T00:34:00.210715+00:00
License: CC0
· commercial use OK